Additional Phase 3 readouts are expected through 2026 and 2027
Retatrutide works by mimicking the actions of three important hormones: GLP-1, GIP and GCG
Comparing GLP-1 Receptor Agonists with Other Diabetes Treatments When considering treatment options for type 2 diabetes, GLP-1 receptor agonists offer distinct advantages compared with other glucose-lowering therapies, though the optimal choice depends on individual patient characteristics, preferences, and clinical circumstances
Their smaller molecular structure also facilitates better tissue penetration and lower production costs, which could enhance accessibility to these novel medications
Hence, DMRS has strong potential and feasibility for in vivo metabolic imaging
is increasing due to growing DTC marketing